FRAX prognostic and intervention thresholds in the management of major bone fractures in hemodialysis patients: A two-year prospective multicenter cohort study.


Journal

Bone
ISSN: 1873-2763
Titre abrégé: Bone
Pays: United States
ID NLM: 8504048

Informations de publication

Date de publication:
04 2020
Historique:
received: 12 08 2019
revised: 01 12 2019
accepted: 10 12 2019
pubmed: 18 12 2019
medline: 22 6 2021
entrez: 18 12 2019
Statut: ppublish

Résumé

The usefulness of FRAX in predicting major bone fractures in patients with end-stage kidney disease on maintenance hemodialysis treatment has been confirmed in previous studies. For meaningful clinical use, the prognostic and intervention FRAX thresholds need to be established. The primary aim of our study was to calculate the optimal cut-off point of FRAX for the best prediction of an increased bone fracture risk in dialysis patients and additionally, to propose its intervention threshold, indicating the need for antifracture pharmacological treatment. The study included 718 hemodialysis patients, who were followed up for two years. Thirty low-energy major bone fractures were diagnosed during the study period. We used the Polish version of FRAX (without the DXA examination) and some particular variables of the FRAX calculator. The optimal cut-off point for prediction of an increased major bone fracture risk was based on the analysis of the sensitivity and specificity curves of FRAX. The analysis revealed FRAX >5% (sensitivity of 70.0%, specificity of 69.8%) as the prognostic threshold for major bone fractures. Its sensitivity for bone fracture prediction was significantly higher, but specificity lower than those of FRAX ≥10%, used in general Polish population. The reason for this can be an underestimation of bone fracture risk with FRAX in dialysis patients. We conclude that the FRAX prognostic threshold for identification of an increased risk of major bone fractures in hemodialysis patients is >5%. We propose to use this specific value of FRAX as an intervention threshold for pharmacological antifracture treatment in hemodialysis patients.

Identifiants

pubmed: 31843681
pii: S8756-3282(19)30484-3
doi: 10.1016/j.bone.2019.115188
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

115188

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Jerzy Przedlacki (J)

Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Warsaw, Poland. Electronic address: jprzedlacki@wum.edu.pl.

Jolanta Buczyńska-Chyl (J)

Dialysis Unit, Regional Specialist Hospital, Radom, Poland.

Piotr Koźmiński (P)

Fresenius Dialysis Center, Mława, Poland.

Ewa Niemczyk (E)

Department of Internal Medicine, Independent Public Specialist Western Hospital John Paul II, Grodzisk Mazowiecki, Poland; Fresenius Dialysis Center, Płońsk, Poland.

Ewa Wojtaszek (E)

Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.

Edyta Gieglis (E)

Fresenius Dialysis Center, Otwock, Poland.

Paweł Żebrowski (P)

Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.

Andrzej Podgórzak (A)

Department of Nephrology, Mazovia Regional Hospital, Siedlce, Poland.

Jolanta Wściślak (J)

Department of Nephrology, Mazovia Regional Hospital, Siedlce, Poland.

Monika Wieliczko (M)

Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.

Janusz Grochowski (J)

Dialysis Unit, Szpital SPZOZ, Maków Mazowiecki, Poland.

Małgorzata Kędzierska (M)

Dialysis Unit, Szpital SPZOZ, Maków Mazowiecki, Poland.

Bożenna Kaczanowska (B)

Dialysis Unit, Szpital Kolejowy, Pruszków, Poland.

Agnieszka Wyszyńska (A)

Dialysis Unit, Szpital Kolejowy, Pruszków, Poland.

Zofia Sitkowska-Kurzec (Z)

Fresenius Dialysis Center, Wołomin, Poland; Fresenius Dialysis Center, Ostrołęka, Poland.

Wiesław Klatko (W)

Dialysis Unit, Specialistic Hospital, Ciechanów, Poland.

Ryszard Gellert (R)

Department of Nephrology and Internal Medicine, Medical Center for Postgraduate Education, Warsaw, Poland.

Dorota Daniewska (D)

Dialysis and Diagnostic Center, Bielański Hospital, Warsaw, Poland.

Dariusz Osuch (D)

Department of Nephrology and Internal Medicine, Medical Center for Postgraduate Education, Warsaw, Poland.

Dariusz Stryjewski (D)

Fresenius Dialysis Center, Płońsk, Poland; Dialysis Unit, Szpital Praski, Warsaw, Poland.

Marek Świtalski (M)

Nephrology Unit, Wojewódzki Szpital Zespolony, Płock, Poland.

Arkadiusz Piotrowski (A)

Nephrology Unit, Wojewódzki Szpital Zespolony, Płock, Poland.

Marek Stopiński (M)

Department of Internal Medicine, Independent Public Specialist Western Hospital John Paul II, Grodzisk Mazowiecki, Poland.

Piotr Kędzierski (P)

Dialysis Unit, B. Brown Avitum Poland, Sp. z o.o., Garwolin, Poland.

Andrzej Rydzewski (A)

Department of Internal Medicine, Nephrology and Transplantation, Central Clinical Hospital of the Ministry of Interior, Warsaw, Poland; Department of Internal Medicine, Nephrology and Transplantation, Centre of Postgraduate Medical Education, Warsaw, Poland.

Bartosz Fiderkiewicz (B)

Department of Internal Medicine, Nephrology and Transplantation, Central Clinical Hospital of the Ministry of Interior, Warsaw, Poland.

Magdalena Wypych-Birecka (M)

Dialysis Unit, Diaverum Polska, Warsaw, Poland.

Dorota Śliwicka (D)

Fresenius Dialysis Center, Sochaczew, Poland.

Magdalena Durlik (M)

Department of Transplantation, Nephrology and Internal Medicine, Medical University of Warsaw, Poland.

Mirosław Grzeszczyk (M)

Department of Transplantation, Nephrology and Internal Medicine, Medical University of Warsaw, Poland.

Antoni Sokalski (A)

Dialysis Unit, Regional Specialist Hospital, Radom, Poland.

Marek Papliński (M)

Nephrology and Dialysis Unit, Szpital Powiatowy Sp. z o.o., Sokołów Podlaski, Poland.

Jakub Hartman (J)

Fresenius Dialysis Center, Ostrów Mazowiecka, Poland.

Jacek Imiela (J)

Department of Internal Medicine, Międzyleski Szpital Specjalistyczny, Warsaw, Poland.

Robert Małecki (R)

Department of Internal Medicine, Międzyleski Szpital Specjalistyczny, Warsaw, Poland.

Agnieszka Bolesta (A)

Department of Internal Medicine, Międzyleski Szpital Specjalistyczny, Warsaw, Poland.

Stanisław Niemczyk (S)

Department of Internal Medicine, Nephrology and Dialysis, Military Medical Institute, Warsaw, Poland.

Wojciech Klimm (W)

Department of Internal Medicine, Nephrology and Dialysis, Military Medical Institute, Warsaw, Poland.

Przemysław Wierzbicki (P)

Internal Medicine and Nephrology Unit with Dialysis Unit, Szpital Powiatowy, Wołomin, Poland.

Joanna Gorczyńska (J)

Internal Medicine and Nephrology Unit with Dialysis Unit, Szpital Powiatowy, Wołomin, Poland.

Mirosław Piórecki (M)

Dialysis Unit, AVOXOVA, Warsaw, Poland.

Sewer Gołębiewski (S)

Dialysis Unit, Wojewódzki Szpital Chirurgii Urazowej św. Anny, Warsaw, Poland.

Roman Horbacz (R)

Fresenius Dialysis Center, Radom, Poland.

Jolanta Małyszko (J)

Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.

Joanna Matuszkiewicz-Rowińska (J)

Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH